Our immunohistochemical analysis showed that almost all CLDN18-ARHGAP26 fusion-positive cases expressed CLDN18, about half of which expressed ARHGAP26 in the membrane, which likely reflects the requirement of CLDN18 promoter activity for expression of the fusion protein in tumor cells. Here, ARHGAP26 is linked to neoplasm.